Image 1SpecificationsOrganism/cell line/tissueHomo sapiens U2OS, RKO, HEK 293T, HeLa, MRC5, K562SexMale or female if applicableSequencer or array typeGPL10123 Agilent-022,060 SurePrint G3 Human CGH Microarray 4x180KData formatRaw dataExperimental factorsEarly S-phase versus Late S-phaseExperimental featuresComparison of replication timing program of 6 human model cell line in order to determine which regions are common or not.

1. Direct link to deposited data {#s0005}
================================

<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80029>.

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Growth protocol {#s0015}
--------------------

### 2.1.1. U2OS cells {#s0020}

The human U2OS cell line was purchased from ATCC and were grown in Dulbecco\'s modified Eagle\'s medium (Invitrogen) with 10% fetal bovine serum (Sigma) at 37 °C, 5% CO~2~ and 5% O~2~.

### 2.1.2. RKO cells {#s0025}

The human RKO cell line was purchased from ATCC and grown in DMEM with GlutaMAX I, high-glucose, sodium pyruvate (Gibco, Life Technologies), supplemented with 10% fetal bovine serum (Lonza), penicillin (100 U ml^− 1^) and streptomycin (100 μg ml^− 1^) (Gibco) at 37 °C, 5% CO~2~ and 5% O~2~.

### 2.1.3. HEK 293T cells {#s0030}

The human HEK 293T cell line was purchased from ATCC and grown at 37 °C in DMEM supplemented with 10% fetal calf serum (FCS) under 5% of CO~2~.

### 2.1.4. HeLa cells {#s0035}

HeLa cells were cultured with the recommended ATCC complete growth medium: Ham\'s F12K medium with [l]{.smallcaps}-glutamine at 2 mM, 1.5 g·l^− 1^ sodium bicarbonate, and 10% of fetal bovine serum in a humidified 5% CO~2~ atmosphere at 37 °C.

### 2.1.5. MRC5-SV cells {#s0040}

The human MRC5-SV cell line was purchased from ATCC and grown in Modified Eagle Medium with GlutaMAX™ I, High glucose, Sodium Pyruvate (Gibco, Life Technologies), supplemented with 10% Fetal Bovine Serum (Lonza), penicillin (100 U/ml) and streptomycin (100 μg/ml) (Gibco) at 37 °C, 5% CO~2~ and 5% O~2~ (standard culture conditions).

### 2.1.6. K562 cells {#s0045}

The cells, from ATCC, grown in Iscove\'s Modified Dulbecco\'s Medium supplemented with 10% fetal bovine serum (Lonza), penicillin (100 U ml^− 1^) and streptomycin (100 μg ml^− 1^) (Gibco) at 37 °C, 5% CO~2~.

2.2. BrDU treatment {#s0050}
-------------------

Cells must be in exponential growing phase. Then they were incubated with BrdU (50 μM) for 90 min, collected, washed three times in DPBS, then fixed in 75% ethanol, and stored at − 20 °C. Fixed cells were first re-suspended in DPBS with RNAseA (0.5 mg/ml) and then with propidium iodide (50 μg/ml) during 30 min minimum at room temperature before the cell sorting.

2.3. Cell sorting {#s0055}
-----------------

100,000 cells were sorted in two fractions S1 and S2 using INFLUX 500 (Cytopeia purchased by BD Biosciences) corresponding to Early and Late fractions respectively. Early fraction corresponds to the small fraction of the end of G1 and a large portion of early S-phase ([Fig. 1](#f0005){ref-type="fig"}). Late fraction corresponds to the large fraction of the late S-phase and a small portion of the beginning of G2/M ([Fig. 1](#f0005){ref-type="fig"}).

2.4. Nascent-DNA extraction {#s0060}
---------------------------

A proteinase K treatment (0.2 mg/ml) was performed in both fractions in lysis buffer (50 mM Tris pH = 8; 10 mM EDTA; 300 mM NaCl) during 2 h at 65 °C in dark condition. Then a phenol-chloroform extraction followed by an ethanol precipitation was performed. The pellet is resuspended in 100 μl of Tris buffer (10 mM). The two fractions were sonicated to obtain fragments between 500 and 1000 bp. DNA is then denatured at 95 °C during 5 min and kept on ice during 10 min. Nascent-DNA was immunoprecipitated using the IP-STAR apparatus with the indirect method option (Diagenode) with BrdU antibodies (10 μg, Anti-BrdU Pure, BD Biosciences, \# 347580). Magnetic beads were prepared as mentioned by the manufacturer (Adamtech; ChIP adambeads \#04342). Beads were washed with different buffers (IP buffer: Tris pH = 8 10 mM; EDTA 1 mM; NaCl 150 mM, Triton × 100 0,5%; Buffer B: Tris pH = 8 20 mM; EDTA 2 mM; NaCl 250 mM; Triton × 100 0,25%). Beads are resuspended in Tris buffer (10 mM). The reversion step was then performed with SDS (1%) and 0.5 mg of proteinase K at 65 °C during 6 h. Nascent-DNA is purified by a pheno-chloroform treatment following by ethanol precipitation. Pellet is resuspended in molecular biology grade H~2~O. To control the quality of enrichment of early and late fractions in S1 and S2, qPCR were performed for all cell lines ([Fig. 2](#f0010){ref-type="fig"}A as example with K562 cell line) with BMP1 oligonucleotides as early control and with DPPA2 oligonucleotides as late control and normalized with amplicon from neo-synthesized mitochondrial DNA. The sequence of oligonucleotides is mentioned by Ryba et al. [@bb0050].

2.5. WGA amplification and labeling {#s0065}
-----------------------------------

Microarray hybridization requires a minimum amount of 500 ng of DNA. To obtain sufficient specific immunoprecipitated nascent-DNA, whole genome amplification was conducted (WGA, Sigma). To confirm that WGA does not introduce bias, a qPCR after whole genome amplification were performed to confirm the specific enrichment in each S1 and S2 fraction for all cell lines ([Fig. 2](#f0010){ref-type="fig"}B as example with K562 cell line). After amplification, early and late fractions were labeled with Cy3 and Cy5 ULS molecules (Genomic DNA labeling Kit, Agilent) as recommended by the manufacturer.

2.6. Hybridization protocol {#s0070}
---------------------------

The hybridization was performed according to the manufacturer instructions on 4 × 180K human microarray (SurePrint G3 Human CGH Microarray Kit, 4x180K, AGILENT Technologies, genome reference Hg18) that covers the whole genome with one probe every 13 Kb (11 Kb in RefSeq sequences).

2.7. Scan protocol {#s0075}
------------------

Microarrays were scanned with an Agilent\'s High-Resolution C Scanner using a resolution of 3 μm and the autofocus option.

2.8. Data processing {#s0080}
--------------------

Feature extraction was performed with the Feature Extraction 9.1 software (Agilent Technologies). For each experiment, the raw data sets were automatically normalized by the Feature extraction software using the CGH_1105_oct12 FE protocol browser. Analysis was performed with the Agilent Genomic Workbench 5.0 software. The log-ratio [@bb0020] timing profiles ([Fig. 3](#f0015){ref-type="fig"}) were smoothed using the Triangular Moving Average option of the Agilent Genomic Workbench 5.0 software with the Triangular algorithm and 500-Kb windows.

The algorithm from CGH applications of the Agilent Genomic Workbench 5.0 software was used in order to determine the replication domains (early and late domains). The aberration detection algorithms associated with the Z-score and with a threshold of 1.8 define the boundaries and magnitudes of the regions of DNA loss or gain corresponding to the late and early replicating domains respectively (Regions with a positive log-ratio is replicated early and late when the log-ratio is negative).

2.9. Global analysis {#s0085}
--------------------

After the determination of Early and Late domains for each cell line, a comparison was conducted to determinate the degree of common domains. The intersection was performed with the Intersection GALAXY tools (Operate on genomic intervals, <https://main.g2.bx.psu.edu/>). In [Fig. 4](#f0020){ref-type="fig"}, color of different regions indicates the degree of similarity between the 6 cell lines.

3. Discussion {#s0090}
=============

Here we provide the DNA replication timing (RT) program of 6 different human model cell lines among which one (K562) is annotated as priority cell line by the ENCODE consortium. Three others are in the third tier group of the ENCODE consortium. Besides of generating the timing profiles for the scientific community, we performed a global analysis to identify some key characteristics of the RT program. First, we show that in the whole genome 50% of CTR domains (constant timing region as defined by Gilbert\'s group) are replicated early and the other 50% are replicated late during the S phase ([Fig. 3](#f0015){ref-type="fig"}). However, we observe that in certain chromosomes, the proportion is unbalanced between early and late domains as in chromosome 17 whom early domains outnumber late domains, and inversely in chromosome 4 for example ([Fig. 3](#f0015){ref-type="fig"}).

We also implemented a global comparison between the 6 replication timing profiles to identify what proportion and which regions of the genome replicate at the same moment during the S-phase within these cell lines ([Fig. 4](#f0020){ref-type="fig"}A and B). We thus show that 50% of the genome is replicated at the same time in the six cell lines ([Fig. 4](#f0020){ref-type="fig"}C). More precisely in chromosomes 17 and 22, around 72% of domains replicate at the same moment during the S-phase ([Table 1](#t0005){ref-type="table"}). These chromosomes have the more robust RT program in comparison to other chromosomes. Conversely chromosome 6 is the most divergent in its RT program between the various model cell line ([Table 1](#t0005){ref-type="table"}). All these data are now available for the scientific community permitting to integrate the replication timing program data in their analyses.
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![FACS analysis profile for K562 cell line used in our experiments as example for the choice of the two S fractions. Green fraction represents the end of G1 and a large portion of early S-phase corresponding to the Early fraction in our experiments. Blue fraction corresponds to a large fraction of the late S-phase and a small portion of the beginning of the G2/M fraction. It is the Late fraction.](gr1){#f0005}

![Quality control of neo-synthetized DNA isolation from K562 cell line by quantitative PCR before WGA amplification (A) and after WGA amplification (B). Oligos BMP1 (noted Early in graph) permit to evaluate early replicated enrichment and DPPA2 (noted Late), Late replicated enrichment. S1 corresponds to Early fraction isolated by cell sorting, S2 to Late fraction.](gr2){#f0010}

![Proportion in % for all 6 cell lines of early and late domains in whole genome and in each chromosome. Red histograms represent early domain and green histograms late domains. Bar errors represent the standard deviation of this proportion in 6 cell lines.](gr3){#f0015}

![Distribution of conserved domains along the genome. The colors used in A, B and C part indicate the degree of conservation between the 6 cell lines. Blue indicates that domains are conserved in all 6 cell lines, green in 5, yellow in 4 and red in only 3. The distribution along each chromosome is indicated (A). A zoom of replication timing program in chromosome 1 is shown (B). The proportion of each conservation category is plotted (C).](gr4){#f0020}

###### 

Proportion of each conserved replication categories in each chromosome.

Table 1

  Number of cell lines with conserved replication domains   6        5        4        3
  --------------------------------------------------------- -------- -------- -------- --------
  chr1                                                      54,55%   21,47%   16,59%   7,39%
  chr2                                                      43,90%   28,90%   18,33%   8,87%
  chr3                                                      47,16%   27,80%   16,32%   8,72%
  chr4                                                      43,32%   29,39%   19,60%   7,69%
  chr5                                                      39,89%   26,94%   24,46%   8,70%
  chr6                                                      39,72%   28,93%   19,62%   11,73%
  chr7                                                      50,70%   25,09%   16,01%   8,20%
  chr8                                                      46,23%   29,98%   15,79%   8,00%
  chr9                                                      40,85%   28,60%   20,81%   9,75%
  chr10                                                     41,11%   24,87%   24,58%   9,44%
  chr11                                                     53,25%   26,42%   13,70%   6,64%
  chr12                                                     51,14%   25,42%   15,64%   7,81%
  chr13                                                     45,67%   26,02%   16,93%   11,38%
  chr14                                                     52,75%   22,80%   16,82%   7,62%
  chr15                                                     56,40%   17,65%   18,38%   7,57%
  chr16                                                     65,09%   18,23%   10,86%   5,81%
  chr17                                                     72,68%   15,58%   8,73%    3,02%
  chr18                                                     45,50%   30,92%   19,15%   4,43%
  chr19                                                     69,18%   10,54%   13,08%   7,21%
  chr20                                                     56,97%   22,23%   14,05%   6,76%
  chr21                                                     43,79%   31,26%   16,78%   8,17%
  chr22                                                     71,50%   10,47%   12,92%   5,10%
  chrX                                                      42,74%   26,68%   21,15%   9,43%
